Clinuvel Pharmaceuticals (ASX:CUV) Median PS Value : A$64.33 (As of Dec. 12, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Clinuvel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$1.732. Clinuvel Pharmaceuticals's 10-Year median PS Ratio is 37.142. Therefore, the Median PS Value for today is A$64.33.

As of today (2024-12-12), Clinuvel Pharmaceuticals's share price is A$12.45. Clinuvel Pharmaceuticals's Median PS Value is A$64.33. Therefore, Clinuvel Pharmaceuticals's Price to Median PS Value for today is 0.19.

The historical rank and industry rank for Clinuvel Pharmaceuticals's Median PS Value or its related term are showing as below:

ASX:CUV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19 Med: 0.29 Max: 0.73
Current: 0.19

During the past 13 years, the highest Price to Median PS Value of Clinuvel Pharmaceuticals was 0.73. The lowest was 0.19. And the median was 0.29.

ASX:CUV's Price-to-Median-PS-Value is ranked better than
89.02% of 264 companies
in the Biotechnology industry
Industry Median: 0.7 vs ASX:CUV: 0.19

Clinuvel Pharmaceuticals Median PS Value Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Median PS Value Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Median PS Value

Get a 7-Day Free Trial

42.06

54.45

58.09

64.33

Clinuvel Pharmaceuticals Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Median PS Value	Get a 7-Day Free Trial															54.45	-	58.09	-	64.33

Competitive Comparison of Clinuvel Pharmaceuticals's Median PS Value

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Price-to-Median-PS-Value falls into.

Clinuvel Pharmaceuticals Median PS Value Calculation

Clinuvel Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	1.732	*	37.142
	=	64.33

10-Year Median PS Ratio is 37.142.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$1.732.

Clinuvel Pharmaceuticals (ASX:CUV) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Clinuvel Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	12.45	/	64.33
	=	0.19

Clinuvel Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany UR9:Germany UR9:Germany

Address

535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

No Headlines